The deal will join CGI's portfolio of cancer tests and lab services with NovellusDx's technologies for cancer treatment response prediction.
The company is continuing to work with a financial advisor to evaluate strategic options, with discussions about potential transactions ongoing.
The increase was drive by revenue growth in Cancer Genetics' discovery services unit, which included the impact of recently acquired CRO VivoPharm.
The firm is selling BioServe to Reprocell as part of Cancer Genetics' transformation and strategic plan to bring itself to profitability.
Near-term, the firm is focused on its cost structure and growing its top line with a view to becoming profitable, according to its interim CEO.
The test is designed to identify a tumor's tissue of origin by assessing 2,000 individual genes and covers 15 common tumor types.
The lawsuits allege the company made false and/or misleading statement and/or failed to disclose information that was pertinent to investors.
The firm is in the midst of evaluating its strategic options and has hired Raymond James to assist in the process, which could include the sale of the firm, it said.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.